Efficacy of recombinant interleukin-2 (rIL-2) in patients with advanced HIV-1 infection and blunted immune response to HAART

The primary endpoint was median change in CD4 + T-cell counts at the end of treatment as compared to baseline

Manuel Crespo; Isabel Caragol; Vicenç Falcó; Esteban Ribera; Susana Urban; Albert Pahissa

2008

Scholarcy highlights

  • The primary endpoint was median change in CD4 + T-cell counts at the end of treatment as compared to baseline

Need more features? Save interactive summary cards to your Scholarcy Library.